These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24559124)

  • 1. The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases.
    Toussirot É; Bereau M
    Inflamm Allergy Drug Targets; 2014; 13(2):121-7. PubMed ID: 24559124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JC Polyomavirus Infection Potentiated by Biologics.
    Multani A; Ho DY
    Infect Dis Clin North Am; 2020 Jun; 34(2):359-388. PubMed ID: 32444013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
    Berger JR; Houff SA; Major EO
    MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.
    Tan CS; Koralnik IJ
    Lancet Neurol; 2010 Apr; 9(4):425-37. PubMed ID: 20298966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Bertoli D; Sottini A; Capra R; Scarpazza C; Bresciani R; Notarangelo LD; Imberti L
    Sci Rep; 2019 Nov; 9(1):16605. PubMed ID: 31719595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy.
    Weissert R
    J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression increases latent infection of brain by JC polyomavirus.
    Bayliss J; Karasoulos T; Bowden S; Glogowski I; McLean CA
    Pathology; 2011 Jun; 43(4):362-7. PubMed ID: 21532525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
    Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
    J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of infections by the human polyomavirus JC: past, present and future.
    Hou J; Major E
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):629-40. PubMed ID: 16107201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive multifocal leukoencephalopathy.
    Berger JR
    Curr Neurol Neurosci Rep; 2007 Nov; 7(6):461-9. PubMed ID: 17999891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR; Stüve O
    Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).
    Bauer J; Gold R; Adams O; Lassmann H
    Acta Neuropathol; 2015 Dec; 130(6):751-64. PubMed ID: 26323992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy.
    Bayliss J; Karasoulos T; McLean CA
    J Infect Dis; 2013 Jan; 207(1):133-6. PubMed ID: 23112281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.
    Chahin S; Berger JR
    J Neurovirol; 2015 Dec; 21(6):623-31. PubMed ID: 25404234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
    Clavel G; Moulignier A; Semerano L
    Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy: new concepts.
    Lima MA
    Arq Neuropsiquiatr; 2013 Sep; 71(9B):699-702. PubMed ID: 24141508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. History and current concepts in the pathogenesis of PML.
    Major EO
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S3-7. PubMed ID: 22123932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
    Tyler KL; Khalili K
    Rev Neurol Dis; 2005; 2(3):144-9. PubMed ID: 16400315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.